Expandi Limited and Kompass Announce Strategic Alliance to Transform B2B Marketing, Advertising and Data Solutions
Expandi Limited, Europe’s most recognized B2B MarTech and AdTech vendor and one of the leading worldwide, and Kompass, a global leader in B2B SalesTech and MarTech solutions and editor of the marketplace www.kompass.com, have entered a groundbreaking alliance. This partnership aims to redefine how businesses connect, market, and grow by leveraging cutting-edge technology and unparalleled data resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250526650205/en/
The agreement covers multiple strategic areas that will deliver innovative solutions to the B2B market:
Key Areas of Collaboration
- Innovative B2B Platform
The partnership will integrate Expandi's B2B Stars platform with www.Kompass.com, one of Europe’s most accurate and populated B2B marketplace. This integration will create a comprehensive "find and be found" solution, enabling companies worldwide to connect with trustworthy partners based on reliable criteria such as verified reviews, financial ratings, and industry awards. - Targeted Advertising on Kompass.com
Expandi's advanced digital advertising solutions, including AccountInsight, will be deployed on kompass.com, one of the highest-traffic B2B websites in Europe. Advertisers will benefit from precise targeting capabilities using firmographics, technographics, intent signals, location data, and more—providing unparalleled reach and relevance. Expandi is mandated by Kompass to offer the new premium placement to Expandi’s direct clients in the enterprise space and to Expandi’s network of global media agencies. - Intent Data Synergy
Expandi's Cyance multi-language intent insights platform will be enriched with Kompass's real-time business intelligence powered by AI, and Kompass generated Intent Data. This synergy will provide businesses with deeper insights into buyer behavior, enabling them to identify opportunities early in the decision-making process. - Data Integration for ABM Excellence
Expandi’s award-winning ABM platform, Jabmo, will now incorporate Kompass’s database of over 60 million companies, with smart AI generated business criteria, and 200 million contacts across 70+ countries. This integration further enhance Jabmo targeting capabilities for B2B marketers planning to reach both micro businesses and/or additional regions of the world not yet covered by the current platform. - Advanced Analytics for Business Insights
Kompass’s flagship SalesTech and MarTech solutions, including EasyBusiness, will integrate analytics from B2B Stars on over 3 million companies in the US and Europe, including the Corporate Reputation Score and AI-optimized company reports. These reports highlight strengths and weaknesses based on the world’s most comprehensive database of verified B2B reviews.
A Game-Changing Alliance
The partnership between Expandi Limited and Kompass represents a significant milestone in the evolution of B2B marketing and data-driven solutions. By combining Expandi’s expertise in MarTech and AdTech with Kompass’s unparalleled business intelligence resources, this alliance will empower businesses to achieve new levels of efficiency, precision, and growth.
This alliance is set to redefine the future of B2B marketing by delivering unmatched value through innovation, precision targeting, and actionable insights.
Raffaele Apostoliti, Founder & CEO of Expandi Limited, commented:
"This partnership is a natural fit between two leaders in their respective fields. By integrating our advanced marketing technologies with Kompass's vast global data resources and martech solutions, we are creating a unique ecosystem that will redefine how businesses connect and grow in the digital age."
Patrick Coupier, CEO at Kompass Group, added:
" Kompass has always been at the forefront of providing trusted business data for companies worldwide and smart MarTech and SalesTech SaaS solutions. This partnership marks another key step in this long tradition of innovation. By joining forces with Expandi, we’re combining our global Smart Data capabilities with cutting-edge marketing and advertising technologies to offer even more powerful, insight-driven solutions. Together, we’re redefining how businesses find, connect with, and convert their ideal B2B prospect, locally and globally”
About Expandi Limited
Expandi Limited is one of the leading worldwide providers of B2B MarTech and AdTech solutions, recently awarded as #1 Leader in ABM worldwide by Frost & Sullivan. Recognized for its innovative platforms such as Jabmo (ABM), Cyance (intent data), Accountinsight (DSP for B2B Programmatic Ad)and B2B Stars (AI powered business directory), Expandi empowers businesses to drive smarter marketing strategies through data-driven insights. Most of the Global media agencies and several of the largest B2B companies are using Expandi platforms and insights across the globe.
About Kompass
Kompass is a global B2B SalesTech and MarTech enabler, providing smart prospecting and lead generation solutions to help companies grow faster, locally and internationally. With a trusted, GDPR-compliant database of over 60 million companies,200 million contacts in 70+ countries, and more than 4 M unique visitors on its marketplace, www.Kompass.com, Kompass empowers businesses with powerful tools like EasyBusiness, KSales and targeted advertising services. From Smart Data to global visibility, Kompass is “your route to business, worldwide”.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526650205/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom